Circulating mir‐320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk
miRNAs play a central role in the complex signaling network of cancer cells with the tumor microenvironment. Little is known on the origin of circulating miRNAs and their relationship with the tumor microenvironment in lung cancer. Here, we focused on the cellular source and relative contribution of...
Saved in:
Published in | International journal of cancer Vol. 144; no. 11; pp. 2746 - 2761 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken, USA
John Wiley & Sons, Inc
01.06.2019
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
ISSN | 0020-7136 1097-0215 1097-0215 |
DOI | 10.1002/ijc.31988 |
Cover
Abstract | miRNAs play a central role in the complex signaling network of cancer cells with the tumor microenvironment. Little is known on the origin of circulating miRNAs and their relationship with the tumor microenvironment in lung cancer. Here, we focused on the cellular source and relative contribution of different cell types to circulating miRNAs composing our risk classifier of lung cancer using in vitro/in vivo models and clinical samples. A cell‐type specific expression pattern and topography of several miRNAs such as mir‐145 in fibroblasts, mir‐126 in endothelial cells, mir‐133a in skeletal muscle cells was observed in normal and lung cancer tissues. Granulocytes and platelets are the major contributors of miRNAs release in blood. miRNAs modulation observed in plasma of lung cancer subjects was consistent with de‐regulation of the same miRNAs observed during immunosuppressive conversion of immune cells. In particular, activated neutrophils showed a miRNA profile mirroring that observed in plasma of lung cancer subjects. Interestingly mir‐320a secreted by neutrophils of high‐risk heavy‐smokers promoted an M2‐like protumorigenic phenotype through downregulation of STAT4 when shuttled into macrophages. These findings suggest a multifactorial and nonepithelial cell‐autonomous origin of circulating miRNAs associated with risk of lung cancer and that circulating miRNAs may act in paracrine signaling with causative role in lung carcinogenesis and immunosuppression.
What's new?
microRNAs play a central role in the complex signaling network of cancer cells with the tumor microenvironment. However, little is known on the origin of circulating miRNAs and their mechanisms of action. This study found a multifactorial and non‐epithelial cell‐autonomous origin of circulating miRNAs associated with lung cancer risk. The findings also suggest a link between an immunosuppressive and pro‐tumorigenic microenvironment and modulation of circulating miRNAs associated with lung cancer risk. The authors propose a novel mechanism whereby miRNA released by neutrophils induce macrophage polarization to support lung cancer growth, highlighting the potential for reprogramming macrophages toward an anti‐tumor polarization. |
---|---|
AbstractList | miRNAs play a central role in the complex signaling network of cancer cells with the tumor microenvironment. Little is known on the origin of circulating miRNAs and their relationship with the tumor microenvironment in lung cancer. Here, we focused on the cellular source and relative contribution of different cell types to circulating miRNAs composing our risk classifier of lung cancer using
in vitro/in vivo
models and clinical samples. A cell‐type specific expression pattern and topography of several miRNAs such as mir‐145 in fibroblasts, mir‐126 in endothelial cells, mir‐133a in skeletal muscle cells was observed in normal and lung cancer tissues. Granulocytes and platelets are the major contributors of miRNAs release in blood. miRNAs modulation observed in plasma of lung cancer subjects was consistent with de‐regulation of the same miRNAs observed during immunosuppressive conversion of immune cells. In particular, activated neutrophils showed a miRNA profile mirroring that observed in plasma of lung cancer subjects. Interestingly mir‐320a secreted by neutrophils of high‐risk heavy‐smokers promoted an M2‐like protumorigenic phenotype through downregulation of STAT4 when shuttled into macrophages. These findings suggest a multifactorial and nonepithelial cell‐autonomous origin of circulating miRNAs associated with risk of lung cancer and that circulating miRNAs may act in paracrine signaling with causative role in lung carcinogenesis and immunosuppression.
What's new?
microRNAs play a central role in the complex signaling network of cancer cells with the tumor microenvironment. However, little is known on the origin of circulating miRNAs and their mechanisms of action. This study found a multifactorial and non‐epithelial cell‐autonomous origin of circulating miRNAs associated with lung cancer risk. The findings also suggest a link between an immunosuppressive and pro‐tumorigenic microenvironment and modulation of circulating miRNAs associated with lung cancer risk. The authors propose a novel mechanism whereby miRNA released by neutrophils induce macrophage polarization to support lung cancer growth, highlighting the potential for reprogramming macrophages toward an anti‐tumor polarization. miRNAs play a central role in the complex signaling network of cancer cells with the tumor microenvironment. Little is known on the origin of circulating miRNAs and their relationship with the tumor microenvironment in lung cancer. Here, we focused on the cellular source and relative contribution of different cell types to circulating miRNAs composing our risk classifier of lung cancer using in vitro/in vivo models and clinical samples. A cell-type specific expression pattern and topography of several miRNAs such as mir-145 in fibroblasts, mir-126 in endothelial cells, mir-133a in skeletal muscle cells was observed in normal and lung cancer tissues. Granulocytes and platelets are the major contributors of miRNAs release in blood. miRNAs modulation observed in plasma of lung cancer subjects was consistent with de-regulation of the same miRNAs observed during immunosuppressive conversion of immune cells. In particular, activated neutrophils showed a miRNA profile mirroring that observed in plasma of lung cancer subjects. Interestingly mir-320a secreted by neutrophils of high-risk heavy-smokers promoted an M2-like protumorigenic phenotype through downregulation of STAT4 when shuttled into macrophages. These findings suggest a multifactorial and nonepithelial cell-autonomous origin of circulating miRNAs associated with risk of lung cancer and that circulating miRNAs may act in paracrine signaling with causative role in lung carcinogenesis and immunosuppression.miRNAs play a central role in the complex signaling network of cancer cells with the tumor microenvironment. Little is known on the origin of circulating miRNAs and their relationship with the tumor microenvironment in lung cancer. Here, we focused on the cellular source and relative contribution of different cell types to circulating miRNAs composing our risk classifier of lung cancer using in vitro/in vivo models and clinical samples. A cell-type specific expression pattern and topography of several miRNAs such as mir-145 in fibroblasts, mir-126 in endothelial cells, mir-133a in skeletal muscle cells was observed in normal and lung cancer tissues. Granulocytes and platelets are the major contributors of miRNAs release in blood. miRNAs modulation observed in plasma of lung cancer subjects was consistent with de-regulation of the same miRNAs observed during immunosuppressive conversion of immune cells. In particular, activated neutrophils showed a miRNA profile mirroring that observed in plasma of lung cancer subjects. Interestingly mir-320a secreted by neutrophils of high-risk heavy-smokers promoted an M2-like protumorigenic phenotype through downregulation of STAT4 when shuttled into macrophages. These findings suggest a multifactorial and nonepithelial cell-autonomous origin of circulating miRNAs associated with risk of lung cancer and that circulating miRNAs may act in paracrine signaling with causative role in lung carcinogenesis and immunosuppression. miRNAs play a central role in the complex signaling network of cancer cells with the tumor microenvironment. Little is known on the origin of circulating miRNAs and their relationship with the tumor microenvironment in lung cancer. Here, we focused on the cellular source and relative contribution of different cell types to circulating miRNAs composing our risk classifier of lung cancer using in vitro/in vivo models and clinical samples. A cell‐type specific expression pattern and topography of several miRNAs such as mir‐145 in fibroblasts, mir‐126 in endothelial cells, mir‐133a in skeletal muscle cells was observed in normal and lung cancer tissues. Granulocytes and platelets are the major contributors of miRNAs release in blood. miRNAs modulation observed in plasma of lung cancer subjects was consistent with de‐regulation of the same miRNAs observed during immunosuppressive conversion of immune cells. In particular, activated neutrophils showed a miRNA profile mirroring that observed in plasma of lung cancer subjects. Interestingly mir‐320a secreted by neutrophils of high‐risk heavy‐smokers promoted an M2‐like protumorigenic phenotype through downregulation of STAT4 when shuttled into macrophages. These findings suggest a multifactorial and nonepithelial cell‐autonomous origin of circulating miRNAs associated with risk of lung cancer and that circulating miRNAs may act in paracrine signaling with causative role in lung carcinogenesis and immunosuppression. What's new? microRNAs play a central role in the complex signaling network of cancer cells with the tumor microenvironment. However, little is known on the origin of circulating miRNAs and their mechanisms of action. This study found a multifactorial and non‐epithelial cell‐autonomous origin of circulating miRNAs associated with lung cancer risk. The findings also suggest a link between an immunosuppressive and pro‐tumorigenic microenvironment and modulation of circulating miRNAs associated with lung cancer risk. The authors propose a novel mechanism whereby miRNA released by neutrophils induce macrophage polarization to support lung cancer growth, highlighting the potential for reprogramming macrophages toward an anti‐tumor polarization. miRNAs play a central role in the complex signaling network of cancer cells with the tumor microenvironment. Little is known on the origin of circulating miRNAs and their relationship with the tumor microenvironment in lung cancer. Here, we focused on the cellular source and relative contribution of different cell types to circulating miRNAs composing our risk classifier of lung cancer using in vitro/in vivo models and clinical samples. A cell-type specific expression pattern and topography of several miRNAs such as mir-145 in fibroblasts, mir-126 in endothelial cells, mir-133a in skeletal muscle cells was observed in normal and lung cancer tissues. Granulocytes and platelets are the major contributors of miRNAs release in blood. miRNAs modulation observed in plasma of lung cancer subjects was consistent with de-regulation of the same miRNAs observed during immunosuppressive conversion of immune cells. In particular, activated neutrophils showed a miRNA profile mirroring that observed in plasma of lung cancer subjects. Interestingly mir-320a secreted by neutrophils of high-risk heavy-smokers promoted an M2-like protumorigenic phenotype through downregulation of STAT4 when shuttled into macrophages. These findings suggest a multifactorial and nonepithelial cell-autonomous origin of circulating miRNAs associated with risk of lung cancer and that circulating miRNAs may act in paracrine signaling with causative role in lung carcinogenesis and immunosuppression. |
Author | Sozzi, Gabriella Facchinetti, Federica Caleca, Laura Verri, Carla Conte, Davide Castelli, Chiara Borzi, Cristina Tripodo, Claudio Huber, Veronica Boeri, Mattia Andriani, Francesca Camisaschi, Chiara Pastorino, Ugo Fortunato, Orazio Roz, Luca Centonze, Giovanni Cancila, Valeria Moro, Massimo Cova, Agata Milione, Massimo |
AuthorAffiliation | 1 Tumor Genomics Unit, Department of Research Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy 5 Tumor Immunology Unit, Department of Health Science, Human Pathology Section University of Palermo School of Medicine Milan Italy 4 Unit of Immunotherapy of Human Tumors, Department of Research Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy 3 Unit of Molecular Bases of Genetic Risk and Genetic Testing, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy Milan Italy 2 Anatomic Pathology Unit, Department of Pathology and Laboratory Medicine Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy 6 Thoracic Surgery Unit, Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy |
AuthorAffiliation_xml | – name: 1 Tumor Genomics Unit, Department of Research Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy – name: 4 Unit of Immunotherapy of Human Tumors, Department of Research Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy – name: 2 Anatomic Pathology Unit, Department of Pathology and Laboratory Medicine Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy – name: 6 Thoracic Surgery Unit, Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy – name: 5 Tumor Immunology Unit, Department of Health Science, Human Pathology Section University of Palermo School of Medicine Milan Italy – name: 3 Unit of Molecular Bases of Genetic Risk and Genetic Testing, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy Milan Italy |
Author_xml | – sequence: 1 givenname: Orazio surname: Fortunato fullname: Fortunato, Orazio organization: Fondazione IRCCS Istituto Nazionale dei Tumori – sequence: 2 givenname: Cristina surname: Borzi fullname: Borzi, Cristina organization: Fondazione IRCCS Istituto Nazionale dei Tumori – sequence: 3 givenname: Massimo surname: Milione fullname: Milione, Massimo organization: Fondazione IRCCS Istituto Nazionale dei Tumori – sequence: 4 givenname: Giovanni surname: Centonze fullname: Centonze, Giovanni organization: Fondazione IRCCS Istituto Nazionale dei Tumori – sequence: 5 givenname: Davide surname: Conte fullname: Conte, Davide organization: Fondazione IRCCS Istituto Nazionale dei Tumori – sequence: 6 givenname: Mattia surname: Boeri fullname: Boeri, Mattia organization: Fondazione IRCCS Istituto Nazionale dei Tumori – sequence: 7 givenname: Carla surname: Verri fullname: Verri, Carla organization: Fondazione IRCCS Istituto Nazionale dei Tumori – sequence: 8 givenname: Massimo surname: Moro fullname: Moro, Massimo organization: Fondazione IRCCS Istituto Nazionale dei Tumori – sequence: 9 givenname: Federica surname: Facchinetti fullname: Facchinetti, Federica organization: Fondazione IRCCS Istituto Nazionale dei Tumori – sequence: 10 givenname: Francesca surname: Andriani fullname: Andriani, Francesca organization: Fondazione IRCCS Istituto Nazionale dei Tumori – sequence: 11 givenname: Luca surname: Roz fullname: Roz, Luca organization: Fondazione IRCCS Istituto Nazionale dei Tumori – sequence: 12 givenname: Laura surname: Caleca fullname: Caleca, Laura organization: Unit of Molecular Bases of Genetic Risk and Genetic Testing, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy – sequence: 13 givenname: Veronica surname: Huber fullname: Huber, Veronica organization: Fondazione IRCCS Istituto Nazionale dei Tumori – sequence: 14 givenname: Agata surname: Cova fullname: Cova, Agata organization: Fondazione IRCCS Istituto Nazionale dei Tumori – sequence: 15 givenname: Chiara surname: Camisaschi fullname: Camisaschi, Chiara organization: Fondazione IRCCS Istituto Nazionale dei Tumori – sequence: 16 givenname: Chiara surname: Castelli fullname: Castelli, Chiara organization: Fondazione IRCCS Istituto Nazionale dei Tumori – sequence: 17 givenname: Valeria surname: Cancila fullname: Cancila, Valeria organization: University of Palermo School of Medicine – sequence: 18 givenname: Claudio surname: Tripodo fullname: Tripodo, Claudio organization: University of Palermo School of Medicine – sequence: 19 givenname: Ugo surname: Pastorino fullname: Pastorino, Ugo organization: Thoracic Surgery Unit, Fondazione IRCCS Istituto Nazionale dei Tumori – sequence: 20 givenname: Gabriella orcidid: 0000-0001-9360-6914 surname: Sozzi fullname: Sozzi, Gabriella email: gabriella.sozzi@istitutotumori.mi.it organization: Fondazione IRCCS Istituto Nazionale dei Tumori |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30426475$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc1u1DAQxy1URLeFAy-ALHGBQ9rxRxLngoRWfBQVcendcpzZXW8TO9hJq73xCDwjT4KXLRVUgpNlzW9-mpn_CTnywSMhzxmcMQB-7rb2TLBGqUdkwaCpC-CsPCKLXIOiZqI6JicpbQEYK0E-IccCJK9kXS7I9dJFO_dmcn5NBxd_fPsuOBg6xjCECRN1wzD7kOZxjJiSu0E6GBvDuDHrXP3M6bhBH6bdiNSkFKwzE3b01k0b2s_ZaY23GGl06fopebwyfcJnd-8puXr_7mr5sbj88uFi-faysFIKVXCGrBFVha1ilmNjWlN3XHFRi7Zaya6TjFe1BKVkK9DU1uZvx2FlUTSdEqfkzUE7zu2AnUU_RdPrMbrBxJ0Oxum_K95t9Drc6KpsgFcsC17dCWL4OmOa9OCSxb43HsOcNGdCSAlNWWb05QN0G-bo83aacxC1YpLvhS_-nOh-lN8xZOD1AciXTSni6h5hoPcR6xyx_hVxZs8fsNZNOb-wX8b1_-u4dT3u_q3WF5-Wh46ffPG5yA |
CitedBy_id | crossref_primary_10_1172_JCI158352 crossref_primary_10_1186_s13046_021_02040_3 crossref_primary_10_1186_s12951_024_03088_x crossref_primary_10_1016_j_jtho_2023_08_019 crossref_primary_10_3389_fimmu_2024_1452078 crossref_primary_10_1080_21655979_2022_2061295 crossref_primary_10_1093_carcin_bgad061 crossref_primary_10_3390_ijms20071611 crossref_primary_10_1016_j_healun_2023_08_011 crossref_primary_10_1039_D1BM01797G crossref_primary_10_3390_cancers11091380 crossref_primary_10_3892_ijo_2020_5108 crossref_primary_10_3390_cancers13071493 crossref_primary_10_3390_ph15030297 crossref_primary_10_1002_1878_0261_13336 crossref_primary_10_1002_jcp_28744 crossref_primary_10_1016_j_lungcan_2019_04_001 crossref_primary_10_3390_ijms21197117 crossref_primary_10_1002_iid3_341 crossref_primary_10_3892_etm_2022_11477 crossref_primary_10_62347_JAYK5667 crossref_primary_10_3389_fonc_2022_911613 crossref_primary_10_1016_j_annonc_2022_01_008 crossref_primary_10_1002_1878_0261_13036 crossref_primary_10_2217_bmm_2023_0215 crossref_primary_10_1166_jbn_2022_3352 crossref_primary_10_3390_cancers11060888 crossref_primary_10_2174_0122115366296148240530072346 crossref_primary_10_3390_biomedicines11030736 crossref_primary_10_3390_ph14020089 crossref_primary_10_1016_j_semcdb_2021_04_001 crossref_primary_10_1155_2024_7484645 crossref_primary_10_1631_jzus_B1900452 crossref_primary_10_3389_fcell_2021_643942 crossref_primary_10_1007_s12672_025_02054_9 crossref_primary_10_3390_ijms25042331 crossref_primary_10_1016_j_biopha_2020_110369 crossref_primary_10_1016_j_yexmp_2020_104411 crossref_primary_10_1093_bib_bbac397 crossref_primary_10_1016_j_prp_2022_154053 crossref_primary_10_1186_s13046_019_1122_2 crossref_primary_10_3390_ijms22020746 crossref_primary_10_1128_mSystems_00724_20 crossref_primary_10_3389_fimmu_2020_01391 crossref_primary_10_1016_j_lanepe_2024_101070 crossref_primary_10_1016_j_jid_2022_01_030 crossref_primary_10_3390_ph13120438 crossref_primary_10_1111_cas_16113 crossref_primary_10_3390_cancers14020435 crossref_primary_10_1016_j_intimp_2019_105880 crossref_primary_10_1158_1055_9965_EPI_22_0689 crossref_primary_10_1016_j_prp_2023_154906 crossref_primary_10_3390_ijms23105297 |
Cites_doi | 10.1007/s10555-007-9066-y 10.1158/1541-7786.MCR-12-0634-T 10.1093/annonc/mdx033 10.1038/nrc1877 10.1016/j.rmed.2015.02.006 10.4049/jimmunol.166.7.4446 10.1038/nrc1256 10.7554/eLife.05005 10.1093/nar/gkw116 10.1183/09031936.02.00089802 10.3332/ecancer.2017.717 10.1101/gr.082701.108 10.1016/j.intimp.2010.08.012 10.1186/1476-4598-12-154 10.1056/NEJMoa1504627 10.1158/1940-6207.CAPR-11-0370 10.1111/jth.12730 10.1038/nri2448 10.1038/ncomms14381 10.1016/j.it.2016.01.004 10.1038/ncb2396 10.1038/srep35250 10.1172/JCI59643 10.1073/pnas.1100048108 10.1038/nri978 10.1007/s12032-011-9923-y 10.1164/rccm.200607-984PP 10.1002/emmm.201100154 10.1097/CEJ.0b013e328351e1b6 10.4049/jimmunol.164.9.4659 10.1136/jclinpath-2015-203005 10.1080/15384047.2017.1281497 10.18632/oncotarget.8676 10.1183/09031936.98.12020380 10.1513/pats.200809-100TH 10.1016/S0140-6736(03)14188-8 10.1038/nm.3394 10.1111/liv.13495 10.1038/nrclinonc.2014.5 10.1038/s41571-018-0111-2 10.1002/emmm.201100209 10.1038/cddis.2014.507 10.1016/S0002-9440(10)65704-5 10.18632/oncotarget.9943 10.18632/oncotarget.5210 10.1158/0008-5472.CAN-14-3781 10.1038/sj.bjc.6605642 10.1080/0284186X.2018.1465585 10.3390/molecules19033038 10.3892/ol.2017.5863 10.1038/nri3088 10.1093/jnci/djv063 10.18632/oncotarget.19996 10.1093/nar/gku461 10.1186/s12864-015-2097-9 10.1200/JCO.2013.50.4357 10.4049/jimmunol.0903879 |
ContentType | Journal Article |
Copyright | 2018 The Authors. published by John Wiley & Sons Ltd on behalf of UICC 2018 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. 2019 UICC |
Copyright_xml | – notice: 2018 The Authors. published by John Wiley & Sons Ltd on behalf of UICC – notice: 2018 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. – notice: 2019 UICC |
DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 7T5 7TO 7U9 H94 K9. 7X8 5PM |
DOI | 10.1002/ijc.31988 |
DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Immunology Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts Oncogenes and Growth Factors Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE AIDS and Cancer Research Abstracts CrossRef |
Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | Circulating mir‐320a promotes immunosuppressive macrophages |
EISSN | 1097-0215 |
EndPage | 2761 |
ExternalDocumentID | PMC6590261 30426475 10_1002_ijc_31988 IJC31988 |
Genre | article Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: Fondazione Umberto Veronesi – fundername: Cariplo Foundation funderid: 2015 n.2015‐0901 – fundername: Ministry of Health funderid: NIH/U01CA166905; RF‐2010 – fundername: Italian Association for Cancer Research funderid: 12162; 16847; 18812; 14318; 15928 – fundername: NCI NIH HHS grantid: U01 CA166905 – fundername: Cariplo Foundation grantid: 2015 n.2015‐0901 – fundername: Ministry of Health grantid: NIH/U01CA166905; RF‐2010 – fundername: Italian Association for Cancer Research grantid: 12162; 16847; 18812; 14318; 15928 |
GroupedDBID | --- -~X .3N .GA 05W 0R~ 10A 1L6 1OB 1OC 1ZS 24P 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 5GY 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHQN AAIPD AAMMB AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABIJN ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCZN ACFBH ACGFO ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEFGJ AEGXH AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFFPM AFGKR AFRAH AFWVQ AFZJQ AGHNM AGXDD AGYGG AHBTC AHMBA AIACR AIAGR AIDQK AIDYY AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EMOBN F00 F01 F04 F5P FUBAC G-S G.N GNP GODZA H.X HBH HGLYW HHY HHZ HZ~ IH2 IX1 J0M JPC KBYEO KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 QRW R.K RIWAO ROL RX1 RYL SUPJJ TEORI UB1 UDS V2E V8K V9Y W2D W8V W99 WBKPD WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WVDHM WXI WXSBR XG1 XPP XV2 ZZTAW ~IA ~WT .55 .GJ .Y3 31~ 3O- 53G 8WZ A6W AANHP AAYXX ABEFU ABEML ACBWZ ACRPL ACSCC ACYXJ ADNMO AGQPQ AHEFC AI. AIQQE ASPBG AVWKF AZFZN BDRZF CITATION EX3 FEDTE GLUZI HF~ HVGLF LW6 M6P PALCI RJQFR SAMSI VH1 WOW X7M Y6R ZGI ZXP AAHHS ACCFJ ADZOD AEEZP AEQDE AIWBW AJBDE CGR CUY CVF ECM EIF NPM 7T5 7TO 7U9 H94 K9. 7X8 5PM |
ID | FETCH-LOGICAL-c4438-21e19366eb81c2e9aba7d282373b6f4dd4126740884b3ea7cc267d20fce39d83 |
IEDL.DBID | DR2 |
ISSN | 0020-7136 1097-0215 |
IngestDate | Thu Aug 21 18:34:34 EDT 2025 Thu Jul 10 23:41:28 EDT 2025 Fri Jul 25 09:27:16 EDT 2025 Thu Apr 03 06:56:32 EDT 2025 Mon Sep 15 11:46:55 EDT 2025 Thu Apr 24 23:02:01 EDT 2025 Sun Sep 21 06:25:44 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | lung cancer microenvironment microRNA |
Language | English |
License | Attribution-NonCommercial 2018 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4438-21e19366eb81c2e9aba7d282373b6f4dd4126740884b3ea7cc267d20fce39d83 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 O.F designed the study, acquired, analyzed and drafted the article; C.B.; G.C.; D.C.; F.F.; M.B.; C.V.; M.Mo.; L.C.;F.A.; V.H.; A.C.; C.Cam.; V.C. acquired and analyzed data; revised critically the article; M.Mi.; L.R.; C.T.; C.Cas.; U.P.; G.S. designed the study, interpreted data, revised critically the article. All the authors approved the final version of the study. |
ORCID | 0000-0001-9360-6914 |
OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fijc.31988 |
PMID | 30426475 |
PQID | 2203781421 |
PQPubID | 105430 |
PageCount | 16 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6590261 proquest_miscellaneous_2133440955 proquest_journals_2203781421 pubmed_primary_30426475 crossref_primary_10_1002_ijc_31988 crossref_citationtrail_10_1002_ijc_31988 wiley_primary_10_1002_ijc_31988_IJC31988 |
PublicationCentury | 2000 |
PublicationDate | 1 June 2019 |
PublicationDateYYYYMMDD | 2019-06-01 |
PublicationDate_xml | – month: 06 year: 2019 text: 1 June 2019 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | Hoboken, USA |
PublicationPlace_xml | – name: Hoboken, USA – name: United States – name: Hoboken |
PublicationTitle | International journal of cancer |
PublicationTitleAlternate | Int J Cancer |
PublicationYear | 2019 |
Publisher | John Wiley & Sons, Inc Wiley Subscription Services, Inc |
Publisher_xml | – name: John Wiley & Sons, Inc – name: Wiley Subscription Services, Inc |
References | 2010; 10 2017; 8 2012; 122 2015; 75 2010; 102 2004; 4 2011; 11 2008; 8 2008; 5 2015; 109 2010; 184 2015; 107 2012; 14 2013; 8 2016; 37 1998; 153 2013; 19 2001; 61 2014; 5 2013; 11 2013; 12 2007; 175 2015; 373 2003; 3 2012; 29 2000; 164 2014; 19 2009; 19 2012; 21 2014; 12 1998; 12 2018; 38 2014; 11 2003; 362 2007; 26 2016; 44 2001; 166 2015; 16 2015; 4 2017; 28 2006; 6 2011; 3 2014; 42 2015; 68 2016; 6 2016; 7 2011; 108 2002; 20 2017; 11 2015; 20 2017; 13 2017; 18 2012; 4 2012; 5 2018; 15 2014; 32 2018; 57 e_1_2_6_51_1 e_1_2_6_53_1 e_1_2_6_32_1 e_1_2_6_19_1 e_1_2_6_13_1 e_1_2_6_36_1 e_1_2_6_59_1 e_1_2_6_11_1 e_1_2_6_34_1 e_1_2_6_17_1 e_1_2_6_55_1 e_1_2_6_15_1 e_1_2_6_38_1 e_1_2_6_57_1 e_1_2_6_43_1 e_1_2_6_20_1 e_1_2_6_41_1 e_1_2_6_60_1 e_1_2_6_9_1 e_1_2_6_5_1 e_1_2_6_7_1 Schmielau J (e_1_2_6_30_1) 2001; 61 e_1_2_6_24_1 e_1_2_6_49_1 e_1_2_6_3_1 e_1_2_6_22_1 e_1_2_6_45_1 e_1_2_6_26_1 e_1_2_6_47_1 e_1_2_6_52_1 e_1_2_6_54_1 e_1_2_6_10_1 e_1_2_6_31_1 e_1_2_6_14_1 e_1_2_6_35_1 e_1_2_6_12_1 e_1_2_6_33_1 e_1_2_6_18_1 e_1_2_6_39_1 e_1_2_6_56_1 e_1_2_6_16_1 e_1_2_6_37_1 e_1_2_6_58_1 e_1_2_6_42_1 e_1_2_6_21_1 e_1_2_6_40_1 e_1_2_6_61_1 Quatromoni JG (e_1_2_6_50_1) 2012; 4 e_1_2_6_8_1 e_1_2_6_6_1 e_1_2_6_25_1 e_1_2_6_48_1 e_1_2_6_23_1 e_1_2_6_2_1 e_1_2_6_29_1 e_1_2_6_44_1 e_1_2_6_27_1 Sestini S (e_1_2_6_28_1) 2015; 20 e_1_2_6_46_1 Massion PP (e_1_2_6_4_1) 2013; 8 |
References_xml | – volume: 20 start-page: 32868 year: 2015 end-page: 77 article-title: Circulating microRNA signature as liquid‐biopsy to monitor lung cancer in low‐dose computed tomography screening publication-title: Oncotarget – volume: 13 start-page: 3247 year: 2017 end-page: 52 article-title: MicroRNA‐320a is downregulated in non‐small cell lung cancer and suppresses tumor cell growth and invasion by directly targeting insulin‐like growth factor 1 receptor publication-title: Oncol Lett – volume: 12 start-page: 1764 year: 2014 end-page: 75 article-title: Platelets in inflammation and immunity publication-title: J Thromb Haemost – volume: 57 start-page: 1225 year: 2018 end-page: 31 article-title: Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab publication-title: Acta Oncol – volume: 5 start-page: 492 year: 2012 end-page: 7 article-title: Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies publication-title: Cancer Prev Res (Phila) – volume: 175 start-page: 547 year: 2007 end-page: 53 article-title: Lung cancer and lung stem cells: strange bedfellows? publication-title: Am J Respir Crit Care Med – volume: 122 start-page: 787 year: 2012 end-page: 95 article-title: Macrophage plasticity and polarization: in vivo veritas publication-title: J Clin Invest – volume: 362 start-page: 593 year: 2003 end-page: 7 article-title: Early lung‐cancer detection with spiral CT and positron emission tomography in heavy smokers: 2‐year results publication-title: Lancet – volume: 5 start-page: e1564 year: 2014 article-title: Mir‐660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2‐p53 interaction publication-title: Cell Death Dis – volume: 4 start-page: 376 year: 2012 end-page: 89 article-title: Tumor‐associated macrophages: function, phenotype, and link to prognosis in human lung cancer publication-title: Am J Transl Res – volume: 6 start-page: 392 year: 2006 end-page: 401 article-title: Fibroblasts in cancer publication-title: Nat Rev Cancer – volume: 3 start-page: 495 year: 2011 end-page: 503 article-title: A serum circulating miRNA diagnostic test to identify asymptomatic high‐risk individuals with early stage lung cancer publication-title: EMBO Mol Med – volume: 21 start-page: 308 year: 2012 end-page: 15 article-title: Annual or biennial CT screening versus observation in heavy smokers: 5‐year results of the MILD trial publication-title: Eur J Cancer Prev – volume: 102 start-page: 1555 year: 2010 end-page: 77 article-title: Guidelines for the welfare and use of animals in cancer research publication-title: Br J Cancer – volume: 68 start-page: 661 year: 2015 end-page: 4 article-title: A novel semi‐automated in situ hybridisation protocol for microRNA detection in paraffin embedded tissue sections publication-title: J Clin Pathol – volume: 42 start-page: 7528 year: 2014 end-page: 38 article-title: Lessons from miR‐143/145: the importance of cell‐type localization of miRNAs publication-title: Nucleic Acids Res – volume: 61 start-page: 4756 year: 2001 end-page: 60 article-title: Activated granulocytes and granulocyte‐derived hydrogen peroxide are the underlying mechanism of suppression of t‐cell function in advanced cancer patients publication-title: Cancer Res – volume: 166 start-page: 4446 year: 2001 end-page: 55 article-title: Inducible expression of Stat4 in dendritic cells and macrophages and its critical role in innate and adaptive immune responses publication-title: J Immunol – volume: 38 start-page: 125 year: 2018 end-page: 35 article-title: Neuropilin‐1 regulated by miR‐320 contributes to the growth and metastasis of cholangiocarcinoma cells publication-title: Liver Int – volume: 164 start-page: 4659 year: 2000 end-page: 64 article-title: Stat4 is expressed in activated peripheral blood monocytes, dendritic cells, and macrophages at sites of Th1‐mediated inflammation publication-title: J Immunol – volume: 12 start-page: 154 year: 2013 article-title: Promoting effect of neutrophils on lung tumorigenesis is mediated by CXCR2 and neutrophil elastase publication-title: Mol Cancer – volume: 8 start-page: 83913 year: 2017 end-page: 24 article-title: Selective secretion of microRNAs from lung cancer cells via extracellular vesicles promotes CAMK1D‐mediated tube formation in endothelial cells publication-title: Oncotarget – volume: 8 start-page: 958 year: 2008 end-page: 69 article-title: Exploring the full spectrum of macrophage activation publication-title: Nat Rev Immunol – volume: 3 start-page: 23 year: 2003 end-page: 35 article-title: Alternative activation of macrophages publication-title: Nat Rev Immunol – volume: 32 start-page: 768 year: 2014 end-page: 73 article-title: Clinical utility of a plasma‐based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study publication-title: J Clin Oncol – volume: 184 start-page: 6545 year: 2010 end-page: 51 article-title: LAG‐3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites publication-title: J Immunol – volume: 4 start-page: 71 year: 2004 end-page: 8 article-title: Tumour‐educated macrophages promote tumour progression and metastasis publication-title: Nat Rev Cancer – volume: 4 year: 2015 article-title: Predicting effective microRNA target sites in mammalian mRNAs publication-title: Elife – volume: 19 start-page: 1423 year: 2013 end-page: 37 article-title: Microenvironmental regulation of tumor progression and metastasis publication-title: Nat Med – volume: 26 start-page: 281 year: 2007 end-page: 90 article-title: Hypoxia: a key regulator of angiogenesis in cancer publication-title: Cancer Metastasis Rev – volume: 20 start-page: 1449 year: 2002 end-page: 56 article-title: Vascular endothelial growth factor mRNA and protein expression in airway epithelial cell lines in vitro publication-title: Eur Respir J – volume: 4 start-page: 143 year: 2012 end-page: 59 article-title: MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review publication-title: EMBO Mol Med – volume: 107 start-page: djv063 year: 2015 article-title: miR‐test: a blood test for lung cancer early detection publication-title: J Natl Cancer Inst – volume: 19 start-page: 3038 year: 2014 end-page: 54 article-title: Assessment of circulating microRNAs in plasma of lung cancer patients publication-title: Molecules – volume: 11 start-page: 750 year: 2011 end-page: 61 article-title: Transcriptional regulation of macrophage polarization: enabling diversity with identity publication-title: Nat Rev Immunol – volume: 7 start-page: 29275 year: 2016 end-page: 86 article-title: MiR‐320a inhibits gastric carcinoma by targeting activity in the FoxM1‐P27KIP1 axis publication-title: Oncotarget – volume: 14 start-page: 159 year: 2012 end-page: 67 article-title: Reprogramming of the tumour microenvironment by stromal PTEN‐regulated miR‐320 publication-title: Nat Cell Biol – volume: 8 start-page: S6 year: 2013 article-title: Biomarker‐driven programs for lung cancer screening (abstract) publication-title: J Thorac Oncol – volume: 7 start-page: 49470 year: 2016 end-page: 80 article-title: Decreased expression of microRNA‐320a promotes proliferation and invasion of non‐small cell lung cancer cells by increasing VDAC1 expression publication-title: Oncotarget – volume: 18 start-page: 142 year: 2017 end-page: 51 article-title: MiR‐320a effectively suppresses lung adenocarcinoma cell proliferation and metastasis by regulating STAT3 signals publication-title: Cancer Biol Ther – volume: 109 start-page: 803 year: 2015 end-page: 12 article-title: MicroRNA as tools and therapeutics in lung cancer publication-title: Respir Med – volume: 12 start-page: 380 year: 1998 end-page: 6 article-title: Inflammatory cells and mediators in bronchial lavage of patients with chronic obstructive pulmonary disease publication-title: Eur Respir J – volume: 15 start-page: 748 year: 2018 end-page: 62 article-title: Hyperprogressive disease: recognizing a novel pattern to improve patient management publication-title: Nat Rev Clin Oncol – volume: 10 start-page: 1325 year: 2010 end-page: 34 article-title: Neutrophils: Cinderella of innate immune system publication-title: Int Immunopharmacol – volume: 28 start-page: 1117 year: 2017 end-page: 23 article-title: European cancer mortality predictions for the year 2017, with focus on lung cancer publication-title: Ann Oncol – volume: 153 start-page: 1903 year: 1998 end-page: 12 article-title: Smoke extract stimulates lung epithelial cells to release neutrophil and monocyte chemotactic activity publication-title: Am J Pathol – volume: 108 start-page: 3713 year: 2011 end-page: 8 article-title: MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer publication-title: Proc Natl Acad Sci USA – volume: 11 start-page: 717 year: 2017 article-title: Circulating and tissue biomarkers in early‐stage non‐small cell lung cancer publication-title: Ecancermedicalscience – volume: 16 start-page: 849 year: 2015 article-title: Novel method to detect microRNAs using chip‐based QuantStudio 3D digital PCR publication-title: BMC Genomics – volume: 11 start-page: 145 year: 2014 end-page: 56 article-title: Clinical relevance of circulating cell‐free microRNAs in cancer publication-title: Nat Rev Clin Oncol – volume: 6 start-page: 35250 year: 2016 article-title: Epithelial cell‐derived microvesicles activate macrophages and promote inflammation via microvesicle‐containing microRNAs publication-title: Sci Rep – volume: 75 start-page: 3636 year: 2015 end-page: 49 article-title: Microenvironment‐modulated metastatic CD133+/CXCR4+/EpCAM‐ lung cancer‐initiating cells sustain tumor dissemination and correlate with poor prognosis publication-title: Cancer Res – volume: 29 start-page: 618 year: 2012 end-page: 26 article-title: High expression of serum miR‐21 and tumor miR‐200c associated with poor prognosis in patients with lung cancer publication-title: Med Oncol – volume: 5 start-page: 811 year: 2008 end-page: 5 article-title: Smoking and lung cancer: the role of inflammation publication-title: Proc Am Thorac Soc – volume: 37 start-page: 208 year: 2016 end-page: 20 article-title: The nature of myeloid‐derived suppressor cells in the tumor microenvironment publication-title: Trends Immunol – volume: 11 start-page: 638 year: 2013 end-page: 50 article-title: Human lung epithelial cells progressed to malignancy through specific oncogenic manipulations publication-title: Mol Cancer Res – volume: 44 start-page: 3865 year: 2016 end-page: 77 article-title: Distribution of miRNA expression across human tissues publication-title: Nucleic Acids Res – volume: 8 start-page: 14381 year: 2017 article-title: Neutrophils dominate the immune cell composition in non‐small cell lung cancer publication-title: Nat Commun – volume: 19 start-page: 92 year: 2009 end-page: 105 article-title: Most mammalian mRNAs are conserved targets of microRNAs publication-title: Genome Res – volume: 373 start-page: 123 year: 2015 end-page: 35 article-title: Nivolumab versus Docetaxel in advanced squamous‐cell non‐small‐cell lung cancer publication-title: N Engl J Med – ident: e_1_2_6_34_1 doi: 10.1007/s10555-007-9066-y – ident: e_1_2_6_17_1 doi: 10.1158/1541-7786.MCR-12-0634-T – ident: e_1_2_6_2_1 doi: 10.1093/annonc/mdx033 – ident: e_1_2_6_35_1 doi: 10.1038/nrc1877 – ident: e_1_2_6_5_1 doi: 10.1016/j.rmed.2015.02.006 – ident: e_1_2_6_44_1 doi: 10.4049/jimmunol.166.7.4446 – ident: e_1_2_6_47_1 doi: 10.1038/nrc1256 – ident: e_1_2_6_21_1 doi: 10.7554/eLife.05005 – ident: e_1_2_6_26_1 doi: 10.1093/nar/gkw116 – volume: 61 start-page: 4756 year: 2001 ident: e_1_2_6_30_1 article-title: Activated granulocytes and granulocyte‐derived hydrogen peroxide are the underlying mechanism of suppression of t‐cell function in advanced cancer patients publication-title: Cancer Res – ident: e_1_2_6_43_1 doi: 10.1183/09031936.02.00089802 – ident: e_1_2_6_3_1 doi: 10.3332/ecancer.2017.717 – ident: e_1_2_6_22_1 doi: 10.1101/gr.082701.108 – ident: e_1_2_6_39_1 doi: 10.1016/j.intimp.2010.08.012 – ident: e_1_2_6_40_1 doi: 10.1186/1476-4598-12-154 – ident: e_1_2_6_60_1 doi: 10.1056/NEJMoa1504627 – ident: e_1_2_6_13_1 doi: 10.1158/1940-6207.CAPR-11-0370 – ident: e_1_2_6_33_1 doi: 10.1111/jth.12730 – ident: e_1_2_6_41_1 doi: 10.1038/nri2448 – ident: e_1_2_6_37_1 doi: 10.1038/ncomms14381 – ident: e_1_2_6_48_1 doi: 10.1016/j.it.2016.01.004 – ident: e_1_2_6_52_1 doi: 10.1038/ncb2396 – ident: e_1_2_6_42_1 doi: 10.1038/srep35250 – ident: e_1_2_6_31_1 doi: 10.1172/JCI59643 – ident: e_1_2_6_8_1 doi: 10.1073/pnas.1100048108 – ident: e_1_2_6_57_1 doi: 10.1038/nri978 – ident: e_1_2_6_46_1 doi: 10.1007/s12032-011-9923-y – ident: e_1_2_6_25_1 doi: 10.1164/rccm.200607-984PP – ident: e_1_2_6_9_1 doi: 10.1002/emmm.201100154 – ident: e_1_2_6_16_1 doi: 10.1097/CEJ.0b013e328351e1b6 – ident: e_1_2_6_59_1 doi: 10.4049/jimmunol.164.9.4659 – ident: e_1_2_6_20_1 doi: 10.1136/jclinpath-2015-203005 – ident: e_1_2_6_55_1 doi: 10.1080/15384047.2017.1281497 – ident: e_1_2_6_51_1 doi: 10.18632/oncotarget.8676 – ident: e_1_2_6_49_1 doi: 10.1183/09031936.98.12020380 – ident: e_1_2_6_12_1 doi: 10.1513/pats.200809-100TH – ident: e_1_2_6_15_1 doi: 10.1016/S0140-6736(03)14188-8 – ident: e_1_2_6_29_1 doi: 10.1038/nm.3394 – ident: e_1_2_6_56_1 doi: 10.1111/liv.13495 – ident: e_1_2_6_6_1 doi: 10.1038/nrclinonc.2014.5 – ident: e_1_2_6_61_1 doi: 10.1038/s41571-018-0111-2 – ident: e_1_2_6_45_1 doi: 10.1002/emmm.201100209 – ident: e_1_2_6_23_1 doi: 10.1038/cddis.2014.507 – ident: e_1_2_6_38_1 doi: 10.1016/S0002-9440(10)65704-5 – ident: e_1_2_6_53_1 doi: 10.18632/oncotarget.9943 – volume: 20 start-page: 32868 year: 2015 ident: e_1_2_6_28_1 article-title: Circulating microRNA signature as liquid‐biopsy to monitor lung cancer in low‐dose computed tomography screening publication-title: Oncotarget doi: 10.18632/oncotarget.5210 – ident: e_1_2_6_36_1 doi: 10.1158/0008-5472.CAN-14-3781 – ident: e_1_2_6_24_1 doi: 10.1038/sj.bjc.6605642 – ident: e_1_2_6_7_1 doi: 10.1080/0284186X.2018.1465585 – ident: e_1_2_6_18_1 doi: 10.3390/molecules19033038 – ident: e_1_2_6_54_1 doi: 10.3892/ol.2017.5863 – ident: e_1_2_6_58_1 doi: 10.1038/nri3088 – ident: e_1_2_6_11_1 doi: 10.1093/jnci/djv063 – ident: e_1_2_6_27_1 doi: 10.18632/oncotarget.19996 – ident: e_1_2_6_14_1 doi: 10.1093/nar/gku461 – ident: e_1_2_6_19_1 doi: 10.1186/s12864-015-2097-9 – ident: e_1_2_6_10_1 doi: 10.1200/JCO.2013.50.4357 – ident: e_1_2_6_32_1 doi: 10.4049/jimmunol.0903879 – volume: 4 start-page: 376 year: 2012 ident: e_1_2_6_50_1 article-title: Tumor‐associated macrophages: function, phenotype, and link to prognosis in human lung cancer publication-title: Am J Transl Res – volume: 8 start-page: S6 year: 2013 ident: e_1_2_6_4_1 article-title: Biomarker‐driven programs for lung cancer screening (abstract) publication-title: J Thorac Oncol |
SSID | ssj0011504 |
Score | 2.530944 |
Snippet | miRNAs play a central role in the complex signaling network of cancer cells with the tumor microenvironment. Little is known on the origin of circulating... |
SourceID | pubmedcentral proquest pubmed crossref wiley |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 2746 |
SubjectTerms | Animals Cancer Carcinogenesis Carcinogenesis - immunology Cell Line, Tumor Circulating MicroRNA - blood Circulating MicroRNA - metabolism Endothelial cells Female Fibroblasts Gene Expression Profiling Gene Expression Regulation, Neoplastic - immunology Health risk assessment Humans Immunosuppression Leukocytes (granulocytic) Leukocytes (neutrophilic) Lung - pathology Lung cancer Lung Neoplasms - blood Lung Neoplasms - genetics Lung Neoplasms - immunology Lung Neoplasms - pathology Macrophages Macrophages - immunology Macrophages - metabolism Male Medical research Mice Mice, SCID microenvironment microRNA MicroRNAs - blood MicroRNAs - metabolism miRNA Molecular Cancer Biology Neutrophils Neutrophils - immunology Neutrophils - metabolism Paracrine signalling Phenotypes Skeletal muscle Stat4 protein STAT4 Transcription Factor - genetics STAT4 Transcription Factor - metabolism Tobacco Smoking - blood Tobacco Smoking - immunology Tumor Escape - genetics Xenograft Model Antitumor Assays |
Title | Circulating mir‐320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fijc.31988 https://www.ncbi.nlm.nih.gov/pubmed/30426475 https://www.proquest.com/docview/2203781421 https://www.proquest.com/docview/2133440955 https://pubmed.ncbi.nlm.nih.gov/PMC6590261 |
Volume | 144 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VHioutJTX9iWDOPSSNnG8diJO1dKqVFqEUJF6QIpsx0vTR3a12e2hp_4EfiO_hBnnUZaChLgl8kR27JnxeDzzDcBbGY76RqIAKt13gVDaBFqgMlRGc5XI1KaacoeHH-XxF3Fy1j9bgndtLkyND9E53EgyvL4mAdem2r8HDS0uLB4404QSfaNYEm7--88ddBQZOg0CcxjgQUy2qEIh3---XNyLHhiYD-Mkf7Vf_QZ0tApf26HXcSeXe_OZ2bO3v6E6_ue_rcGTxjBlBzUnPYUlV67DyrC5en8Gl4Nian2tr_Ibuy6mP-6-xzzUbOLj-VzFCso0GVfzSR1ae-PYtab6YOeosSo25Iyiycbk8mW64QmXM_IDsyvUOMwS_00Zxbo_h9Ojw9PBcdBUagisEKgxeeTQEJTSmSSy3KXaaJVzwsGJjRyJPBcRl0qgRhMmdlpZi685D0fWxWmexC9guRyX7hWwRMo8NCbMkxR1i4i0tQl3CZGj5WJlD3bbJctsg2JOxTSushp_mWc4d5mfux686UgnNXTHn4i22nXPGumtMs7DmKDAeNSD110zyh1dpujSjedIg4d7IQjArwcvazbpeiEXkRQKW9QCA3UEhOm92FIW5x7bWxKcjsR-dz1__H3g2YeTgX_Y-HfSTXiM9l5aR7ptwfJsOnfbaFPNzA484uLTjhehnxcSIKg |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NTtwwEB5RKrVcKvpHt6WtqXrgEpE4XtuRekGrooWyiMNW4hbZjhdCIbvaZTnzCDwjT8KMk01ZQaXeEnkiRx7P-PN4_A3AdxmPulaiASrT9ZFQxkZGoDNU1nClZeYyQ3eHB0ey_1scnHRPVuDH4i5MzQ_RBtzIMoK_JgOngPTOX9bQ8tzhjjPT-hk8F4jLiTmfi-P2DAGhTsPBHEe4FZMLXqGY77SfLq9GjyDm40zJhwg2LEF76_CqwY5st1b2a1jx1Rt4MWhOx9_Cn145daEcV3XKLsvp3c1tymPDJiHlzs9YSZdBxrP5pM5-vfbs0lAJrzN0KjM24IwSvsYUlWWmUZsvGIVq2QU6BeZoikwZpaO_g-Hez2GvHzXFFCInBDo1nnjEalJ6qxPHfWasUQUnqprUypEoCpFwqQQ6HWFTb5Rz-FrweOR8mhU6fQ-r1bjyH4BpKYvY2rjQGZq_SIxzmntN4ggunOzA9mJMc9cQjVO9i4u8pkjmOQ5_Hoa_A99a0UnNrvGU0OZCMXljYLOc8zglti6edGCrbUbToPMOU_nxHGVw_y0Ecex1YKPWY9sLRXGkUNiiljTcChDt9nJLVZ4F-m1JjDcS-90Oc-HfP57vH_TCw8f_F_0KL_vDwWF-uH_06xOsITzL6sS0TVi9ms79Z4RAV_ZLmOn35XYDOA |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NbtQwEB6VVqq4IMrvQgGDOPQSNXG8tqOe0JZVW9iqhyL1FvlvaaDNrna7nHkEnpEn6YyTDV21lbgl8kSOPJ7x5_H4G4CPMh33rUQDVKYfEqGMTYxAZ6is4UrLwhWG7g6PjuXBN3F01j9bg73lXZiGH6ILuJFlRH9NBj71491_pKHVD4cbzkLrB7BBh31Ut4GLk-4IAZFOS8GcJrgTk0taoZTvdp-uLka3EObtRMmbADauQMPH8KiFjuxTo-stWAv1E9gctYfjT-HnoJq5WI2r_s4uq9nf339ynho2jRl3Yc4qugsymS-mTfLrr8AuDVXwOkefMmcjzijfa0JBWWZarQXPKFLLLtAnMEczZMYoG_0ZnA4_nw4OkraWQuKEQJ_Gs4BQTcpgdeZ4KIw1ynNiqsmtHAvvRcalEuhzhM2DUc7hq-fp2IW88Dp_Duv1pA4vgWkpfWpt6nWB1i8y45zmQZM4Ygsne7CzHNPStTzjVO7iomwYknmJw1_G4e_Bh0502pBr3CW0vVRM2drXvOQ8zYmsi2c9eN81o2XQcYepw2SBMrj9FoIo9nrwotFj1wsFcaRQ2KJWNNwJEOv2aktdnUf2bUmENxL73Ylz4f4fLw-PBvHh1f-LvoPNk_1h-fXw-MtreIjgrGjS0rZh_Wq2CG8QAF3Zt3GiXwNKIwJh |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Circulating+mir%E2%80%90320a+promotes+immunosuppressive+macrophages+M2+phenotype+associated+with+lung+cancer+risk&rft.jtitle=International+journal+of+cancer&rft.au=Fortunato%2C+Orazio&rft.au=Borzi%2C+Cristina&rft.au=Milione%2C+Massimo&rft.au=Centonze%2C+Giovanni&rft.date=2019-06-01&rft.issn=0020-7136&rft.eissn=1097-0215&rft.volume=144&rft.issue=11&rft.spage=2746&rft.epage=2761&rft_id=info:doi/10.1002%2Fijc.31988&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_ijc_31988 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0020-7136&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0020-7136&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0020-7136&client=summon |